Novartis Ag (NVS) EBIT Growth (3y) (2012 - 2025)
Novartis Ag (NVS) EBIT Growth (3y) (2012 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EBIT Growth (3y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
81.11% |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
3.64% |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
12.96% |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
18.54% |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
-203.67% |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
11.54% |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
14.90% |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
2.04% |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
- |
| 10 |
Biogen |
30.87 Bn |
26.59 Bn |
1.82 Bn |
-8.06% |
| Date | Value |
|---|
| Jun 30, 2025 |
4.69% |
| Dec 31, 2024 |
229.63% |
| Jun 30, 2024 |
-36.31% |
| Dec 31, 2023 |
-32.96% |
| Jun 30, 2023 |
6.07% |
| Mar 31, 2023 |
4,707.77% |
| Jun 30, 2022 |
79.54% |
| Mar 31, 2022 |
40.37% |
| Dec 31, 2021 |
-23.42% |
| Sep 30, 2021 |
-20.35% |
| Jun 30, 2021 |
84.24% |
| Mar 31, 2021 |
3,146.95% |
| Dec 31, 2020 |
121.57% |
| Sep 30, 2020 |
-24.34% |
| Jun 30, 2020 |
1.04% |
| Mar 31, 2020 |
-26.61% |
| Jun 30, 2019 |
20.79% |
| Mar 31, 2019 |
-99.08% |
| Dec 31, 2018 |
-97.96% |
| Sep 30, 2018 |
65.42% |
